RxDoctor Payments Data

Naktal Hamoud, MD

Clinical Cardiac Electrophysiology · The Woodlands, TXNPI 1922237494

Payments from drug & device makers

$8,207in general payments, 2019–2025

Across 272 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$1K
  • Biosense Webster, Inc.$1K
  • Medtronic$935
  • Atricure, Inc.$439
  • Pfizer$204
  • plus $812 from 10 others

What the payments were for

  • Travel & lodging$1,79622%
  • Food & beverage$6,25276%
  • Other$1582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,207 in reported general payments places this provider in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$206,467
Medicare patients
520
Services billed
2,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$209,297
XareltoRivaroxaban93$113,711
EntrestoSacubitril/Valsartan12$12,540
Dofetilide69$11,382
Flecainide Acetate216$7,834
SotalolSotalol Hcl160$2,964
Amiodarone Hcl109$2,888
Metoprolol Succinate101$2,474
Carvedilol73$1,381
Mexiletine Hcl13$867
Potassium Chloride58$789
Losartan Potassium32$476
Minocycline Hcl49$388
Metoprolol Tartrate62$292
Amlodipine Besylate32$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$209,297189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →